Samsung Biologics Under CEO John Rim Faces New ESG Risk After Rejecting Ruling in Contract Worker Discrimination Case
The Samsung Biologics Labor Union criticized Samsung Biologics after the Incheon Regional Labor Relations Commission, in a discrimination remedy case (Case No. Incheon 2025 Discrimination 10), ruled that the company’s exclusion of contract workers from holiday gift benefits constituted discriminatory treatment, after which the company changed counsel from Bae, Kim & Lee LLC to Kim & Chang and filed for review before the National Labor Relations Commission.
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike.
Samsung Biologics Labor Union Warns of "Structural Supply Chain Risk" Amid Labor Dispute, Highlighting Systemic Governance Failures
The labor dispute at Samsung Biologics, the world’s leading contract development and manufacturing organization (CDMO), has reached a critical juncture. Representing approximately 75% of the company's workforce, the Samsung Biologics Labor Union (President: Jaesung Park) announced today that the ongoing conflict is not merely a wage dispute, but a core business risk stemming from the structural limits of Samsung Group’s opaque corporate governance and labor compliance systems.
